DOCSLIB.ORG

New-And-Emerging-Technologies-For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New-And-Emerging-Technologies-For Horizon Scanning Centre) New and emerging self-sampling technologies for Human Papillomavirus (HPV) testing March 2014 1 This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The NIHR Horizon Scanning Centre, University of Birmingham, United Kingdom [email protected] http://www.hsc.nihr.ac.uk/ Copyright © University of Birmingham 2014 2 CONTENTS CONTENTS Executive summary ………………………………………………………………………… 5 Acknowledgments ....................................................................................................... 5 1. Introduction .............................................................................................................. 6 1.1 NHS Cervical Screening .......................................................................................... 6 1.2 HPV testing .............................................................................................................. 7 1.3 HPV self-sampling …………………………………...…………………………………... 7 1.3.1 Proof of concept ............................................................................................... 8 1.3.2 Technology types ............................................................................................ 9 1.4 Aim & objective …………………………………………………………………………. 10 2. Methods .................................................................................................................. 10 2.1 Inclusion criteria ..................................................................................................... 10 2.2 Review process ...................................................................................................... 11 2.2.1 Identification of technologies ... ...................................................................... 11 2.2.2 Expert advice ................................................................................................. 12 3. Results .................................................................................................................... 12 3.1 Technologies by type.............................................................................................. 13 3.2 Sample transit – dry versus liquid…....................................................................... 13 4. Discussion .............................................................................................................. 14 4.1 The sampling device – what matters? …................................................................ 14 4.1.1 User acceptability ......................................................................................... .15 4.1.2 Sampler design ................................................................................... ……….15 4.1.2.1 Applicator or stick?.................... ........................................................... .15 4.1.2.2 Swab or brush?.................... ................................................................. .16 4.2 Sampling method …………………………………………………………………..…... 17 4.2.1 Instructions for use.................... ..................................................................... 17 4.2.2 Accidental detachment .................................................................................. 17 4.3 Post-sampling method …………………………………………………………………..17 4.3.1 Sample transfer.............................................................................................. 17 4.3.2 Dry or liquid? .................................................................................................. 17 4.3.3 Labelling and consent .................................................................................... 18 4.4 Transportation …………………………………………………………………………... 18 4.4.1 Dry transportation.................... ...................................................................... 18 4.7 Cost……………………............................................................................................ 19 4.8 Innovations in HPV testing……............................................................................... 19 5. Summary ................................................................................................................. 19 3 Appendices Appendix 1 Advisory Group ………………………………………………………………... 20 Appendix 2 Technologies marketed or in development for HPV self-sampling use .... 21 Appendix 3 Technologies that might have potential for HPV self-sampling use …...... 28 Appendix 4 Pictures of some of the technologies ……………………………..……….... 38 References ……………………………………………………………………...…………... 45 4 EXECUTIVE SUMMARY This review aims to identify new and emerging technologies for cervicovaginal self- sampling for human papillomavirus (HPV) testing. Infection with HPV is the main risk factor and a necessary cause of cervical cancer. Cervical cancer is the twelfth most common cancer in women in the UK, and the third most common gynaecological cancer1. It caused 781 deaths in England in 20112. The NHS Cervical Screening Programme screens over three million women in England each year3. In order to identify relevant technologies, the review used five sources of intelligence: 1. Consultation with: • commercial developers. • clinical and scientific experts. • trade associations. 2. Searching: • online sources of information (e.g. clinical trial and bibliographic databases, and the medical media). • NIHR Horizon Scanning Centre in-house technology database. A total of 43 technologies were identified. Of these, 17 are either currently marketed (or are being developed) specifically for self-sampling use. The remaining 26 technologies might have potential for self-sampling use. ACKNOWLEDGEMENTS Internal review team Dr Sara Trevitt Senior Analyst Dr Sue Simpson Associate Director Dr Annette Wood Medical Advisor Advisory Group Ms Catherine Witney NHS Cancer Screening Programmes Mrs Janet Rimmer NHS Cancer Screening Programmes Ms Samantha Fletcher Central Manchester University Hospitals NHS Foundation Trust Dr Kate Cuschieri Scottish HPV Reference Laboratory. 5 1. INTRODUCTION The review was conducted at the request of the NHS Cancer Screening Programmes (a part of Public Health England) to provide an early intelligence report on new and emerging self-sampling technologies that can or could potentially be used for HPV testing. 1.1 NHS CERVICAL SCREENING Cervical screening is a method of preventing cancer by detecting and treating early abnormalities which, if left untreated, could lead to cancer in a woman's cervix (the neck of the womb)4. In England, the NHS Cervical Screening Programme (NHSCSP) offers cervical screening to all women aged between 25 and 64 years. After the first cervical screen, repeat invitations are sent out every three years between the ages of 25 and 49 years and every five years between the ages of 54 and 64 years. Current cervical testing uses a method called liquid-based cytology (LBC). The sample is taken by a healthcare professional (nurse or doctor) in a primary care setting, such as a GP surgery. An instrument called a speculum is inserted into the vagina to hold it open, whilst a small brush-like device is wiped over the cervix to pick up cells. This sample of cells is then placed into a small container of liquid. Obtaining the sample takes a few minutes, and some woman may experience some discomfort or pain. The sample is then sent to a laboratory for the cells to be transferred onto a slide and examined microscopically (called cytology). More than 3.5 million women were screened by the NHS Cervical Screening Programme in England in 2011/20125. According to figures reported in 2012, cervical screening coverage in England (the proportion of women screened within the previous five years) has remained consistently high over the past 20 years5. However, there has been a gradual decline from 82% coverage in the late 1990s to 79% in the five years up to 2012. The fall in coverage of 0.3% (78.6% down to 78.3%) between March 2012 and March 2013 was most notable among women aged 25 to 49 years6. The reasons that women do not attend for screening are complex, but include7: • Emotional/personal barriers, e.g. embarrassment, fear of discomfort or pain, fear of the result, preference for a female nurse/doctor. • Practical and organisational barriers, e.g. travel difficulties, childcare issues, work commitments. • Knowledge/awareness barriers, e.g. lack of understanding about the causes of cervical cancer and the purpose of screening. • Demographic factors, e.g. being from a specific ethnic minority group or a deprived background. Cervical cancer caused 781 deaths in England in 20112. Many women who develop the disease have not been screened regularly, and not undergoing cervical screening is one of the greatest risk factors for developing cervical cancer. Regular cervical screening is the best way to detect changes to the cervix before cancer develops. Early detection and treatment can prevent around 75% of cervical cancers from developing4. 6 Cervical cancer is more common in women who smoke, first had sex at an early age, have had several sexual partners, have had a sexual partner who has had several other partners, or take immunosuppressant drugs. 1.2 HPV TESTING Human papillomavirus (HPV) is a common infection that most women will get at some time in their life. It shows no symptoms. HPV is easily transmitted during intimate sexual contact between partners. There are
Load more

Recommended publications
  • OVESTIN PESSARY (0.5Mg)
    NEW ZEALAND DATA SHEET 1. OVESTIN PESSARY (0.5mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 0.5 mg Estriol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pessary 0.5 mg - white, torpedo formed pessary. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Atrophy of the lower urogenital tract related to oestrogen deficiency, notably • for the treatment of vaginal complaints such as dyspareunia, dryness and itching. • for the prevention of recurrent infections of the vagina and lower urinary tract. • in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery. A diagnostic aid in case of a doubtful atrophic cervical smear. 4.2 Dose and method of administration Dosage OVESTIN is an oestrogen-only product that may be given to women with or without a uterus. Atrophy of the lower urogenital tract 1 pessary per day for the first weeks, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 pessary twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery 1 pessary per day in the 2 weeks before surgery; 1 pessary twice a week in the 2 weeks after surgery. A diagnostic aid in case of a doubtful atrophic cervical smear 1 pessary on alternate days in the week before taking the next smear. Administration OVESTIN pessaries should be inserted intravaginally before retiring at night.
    [Show full text]
  • UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse
    UK Clinical Guideline for best practice in the use of vaginal pessaries for pelvic organ prolapse March 2021 Developed by members of the UK Clinical Guideline Group for the use of pessaries in vaginal prolapse representing: the United Kingdom Continence Society (UKCS); the Pelvic Obstetric and Gynaecological Physiotherapy (POGP); the British Society of Urogynaecology (BSUG); the Association for Continence Advice (ACA); the Scottish Pelvic Floor Network (SPFN); The Pelvic Floor Society (TPFS); the Royal College of Obstetricians and Gynaecologists (RCOG); the Royal College of Nursing (RCN); and pessary users. Funded by grants awarded by UKCS and the Chartered Society of Physiotherapy (CSP). This guideline was completed in December 2020, and following stakeholder review, has been given official endorsement and approval by: • British Association of Urological Nurses (BAUN) • International Urogynecological Association (IUGA) • Pelvic Obstetric and Gynaecological Physiotherapy (POGP) • Scottish Pelvic Floor Network (SPFN) • The Association of Continence Advice (ACA) • The British Society of Urogynaecology (BSUG) • The Pelvic Floor Society (TPFS) • The Royal College of Nursing (RCN) • The Royal College of Obstetricians and Gynaecologists (RCOG) • The United Kingdom Continence Society (UKCS) Review This guideline will be due for full review in 2024. All comments received on the POGP and UKCS websites or submitted here: [email protected] will be included in the review process. 2 Table of Contents Table of Contents ................................................................................................................................
    [Show full text]
  • Impacts of a Ban Or Restrictions in Sale of Items in the EU's Single Use Plastics Directive
    SOCIAL RESEARCH NUMBER: 32/2020 PUBLICATION DATE: 19/05/2020 Preliminary Research to Assess the Impacts of a Ban or Restrictions in Sale in Wales of Items in the EU's Single Use Plastics Directive Mae’r ddogfen yma hefyd ar gael yn Gymraeg. This document is also available in Welsh. © Crown Copyright Digital ISBN 978-1-80038-424-8 Title: Preliminary Research to Assess the Impacts of a Ban or Restrictions in Sale in Wales of Items in the EU's Single Use Plastics Directive Author(s): George Cole, Resource Futures Carla Worth, Resource Futures Katie Powell, Resource Futures Sam Reeve, Resource Futures Susie Stevenson, Miller Research (UK) Nick Morgan, Miller Research (UK) Howard Walker, Bridge Economics Full Research Report: Cole, G; Worth, C; Powell, K; Reeve, S; Stevenson, S; Morgan, N; Walker, H (2019). Preliminary Research to Assess the Impacts of a Ban or Restrictions in Sale in Wales of Items in the EU's Single Use Plastics Directive. Cardiff: Welsh Government, GSR report number 32/2020 Available at: https://gov.wales/impacts-ban-or-restrictions-sale-items-eus-single- use-plastics-directive Views expressed in this report are those of the researcher and not necessarily those of the Welsh Government For further information please contact: Isabella Malet-Lambert Knowledge and Analytical Services Welsh Government Cathays Park Cardiff CF10 3NQ 03000 628250 [email protected] Table of contents List of tables ..........................................................................................................................
    [Show full text]
  • Pessary for Management of Pelvic Organ Prolapse
    Pessary for management of Pelvic Organ Prolapse Cathy Davis Clinical Nurse Specialist Department of Urogynaecology King’s College Hospital, London Definition of Prolapse The descent of one or more of the anterior vaginal wall, posterior vaginal wall, uterus (cervix) or vaginal vault (cuff scar after hysterectomy). The presence of any such sign should be correlated with relevant POP symptoms. (Haylen et al 2016) Risk Factors • Increased intra-abdominal pressure • Chronic cough • Chronic constipation • Weight lifting • Presence of abdominal tumours - fibroids & ovarian cysts • High impact exercise • Age/ Menopause • Obesity Risk Factors contd.... • Smoking • Multiparity • Congenital weakness – rare; due to deficiency in collagen metabolism • Injury to pelvic floor muscles • Iatrogenic/ pelvic surgery - hysterectomy Symptoms of POP • May be asymptomatic – a small amount of prolapse can often be normal • Sensation of a lump or bulge " coming down" - most common • Backache • Heaviness • Dragging or discomfort inside the vagina – often worse on standing /sitting for prolonged periods • Seeing a lump or bulge Symptoms of POP contd.... • Bladder / Urinary symptoms -Frequency -Difficulty initiating voids, low-flow, incomplete bladder emptying -Leakage on certain movements or when lifting heavy objects -Recurrent urinary tract infections • Bowel symptoms -Constipation - Incomplete bowel emptying - May have to digitate to defecate/use aides • Symptoms related to Sex – uncomfortable, lack of sensation Diagnosis of Prolapse • Vaginal examination •
    [Show full text]
  • Combi Soft Gel Pessary & External Cream
    Combi Soft Gel Pessary Canesten & External Cream 500mg vaginal capsule & 2% w/w cream Clotrimazole Read all of this leaflet carefully because it contains important To treat internal thrush, your doctor may recommend that you use the information for you. pessary without the help of an applicator. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. HOW TO USE CANESTEN® COMBI • This medicine has been prescribed for you. Do not give it to anyone else 3. under any circumstances. The Soft Gel Pessary: • If you have any unusual effects after using this product, tell your doctor. Unless directed otherwise by your doctor, the Soft Gel Pessary should be inserted as high as possible into the vagina, preferably before going to sleep IN THIS LEAFLET at night for convenient and comfortable treatment. Wash your hands before removing the foil from the blister pack and again 1. What is Canesten Combi and what is it used for? afterwards when you have used the applicator. 2. Before you use Canesten Combi 3. How to use Canesten Combi 1. Remove the applicator from the packaging. Pull out the plunger A until it 4. Possible side effects stops. Remove the pessary from the foil blister pack and place firmly into the 5. How to store Canesten Combi applicator B. 6. Further information 1. WHAT IS CANESTEN® COMBI AND WHAT IS IT USED FOR? Canesten Combi Soft Gel Pessary & External Cream is a full course of treatment for vaginal thrush (candidiasis) because it treats both the internal cause and external symptoms.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Laserjet All-In-One
    hp LaserJet 3200/3200m printer·· fax copier · scanner user LaserJet guide all-in-one hp LaserJet 3200/3200m product user guide Copyright and License © Hewlett-Packard Company 2001 All Rights Reserved. Except as allowed by copyright laws or herein, reproduction, adaptation, or translation without prior written permission is prohibited. A user of the Hewlett-Packard printer associated with this user guide is granted a license to: a) print hard copies of this user guide for PERSONAL, INTERNAL, or COMPANY use subject to the restriction not to sell, resell, or otherwise distribute the hard copies; and b) place an electronic copy of this user guide on a network server provided access to the electronic copy is limited to PERSONAL, INTERNAL users of the Hewlett-Packard printer associated with this user guide. Third Edition, April 2001 Warranty The information contained in this document is subject to change without notice. Hewlett-Packard makes no warranty of any kind with respect to this information. HEWLETT-PACKARD SPECIFICALLY DISCLAIMS THE IMPLIED WARRANTY OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE Hewlett-Packard shall not be liable for any direct, indirect, incidental, consequential, or other damage alleged in connection with the furnishing or use of this information. NOTICE TO U.S. GOVERNMENT USERS: RESTRICTED RIGHTS COMMERCIAL COMPUTER SOFTWARE: Use, duplication, or disclosure by the Government is subject to restrictions as set forth in subparagraph (c)(1)(ii) of the Rights in Technical Data Clause at DFARS 52.227-7013. Material scanned by this product may be protected by governmental laws and other regulations, such as copyright laws.
    [Show full text]
  • Regulations Governing the Classification of Medical Devices (Draft)
    Regulations Governing the Classification of Medical Devices (Draft) Article 1 These Regulations are enacted pursuant to Paragraph 2, Article 3 of the Medical Devices Act (hereinafter “this Act”). Article 2 Medical devices are classified into the following categories according to their function, intended use, operating instructions, and working principle, depending on the applicable medical specialty: 1. Clinical chemistry and clinical toxicology devices 2. Hematology and pathology devices 3. Immunology and microbiology devices 4. Anesthesiology devices 5. Cardiovascular devices 6. Dental devices 7. Ear, nose, and throat devices 8. Gastroenterology and urology devices 9. General and plastic surgery devices 10. General hospital and personal use devices 11. Neurological devices 12. Obstetrical and gynecological devices 13. Ophthalmic devices 14. Orthopedic devices 15. Physical medicine devices 16. Radiology devices Article 3 Medical devices are classified into the following classes according to their risk level: 1. Class I: Low risk 2. Class II: Medium risk 3. Class III: High risk 1 Article 4 Product items of the medical device classification are specified in the Annex. In addition to rules stated in the Annex, medical devices whose function, intended use, or working principle are special may have their classification determined according to the following rules: 1. If two or more categories, classes, or product items are applicable to the same medical device, the highest class of risk level is assigned. 2. The accessory to a medical device, intended specifically by the manufacturer for use with a particular medical device, is classified the same as the particular medical device, unless otherwise specified in the Annex. 3.
    [Show full text]
  • Vaginal Support Pessaries: Indications for Use and Fitting Strategies
    SERIES Vaginal Support Pessaries: Indications for Use and Fitting Strategies Shanna Atnip and Katharine O’Dell ESSARIES P elvic floor disorders are © 2012 Society of Urologic Nurses and Associates common in women, and as the population ages, Atnip, S., & O’Dell, K. (2012). Vaginal support pessaries: Indications for use and these disorders may be fitting strategies. Urologic Nursing, 32(3), 114-125. Pseen more frequently by health ERIES ON care providers (Nygaard et al., Flexible silicone vaginal support pessaries offer a low-risk, effective option for S 2008). When pelvic symptoms treatment of symptoms of pelvic organ prolapse. This first article in a three-part series summarizes clinical recommendations and current evidence related to are associated with loss of struc- pessary indications, choice, and fitting. tural support of the pelvic organs and vagina, vaginal support pes- PECIAL Key Words: Pelvic organ prolapse, pessary, indications, fitting. saries offer an important option S for relief (American College of Objectives: Obstetricians & Gynecologists 1. List the symptoms of pelvic organ prolapse that may be successfully treated [ACOG], 2007). with a vaginal support pessary. Historically, vaginal pessaries have been used to manage pelvic 2. Discuss the various types of pessaries and their uses to treat pelvic organ floor relaxation and were made prolapse. from a variety of materials, 3. Outline the pessary selection process and steps to pessary fitting. including fruit, metal, porcelain, rubber, and acrylic (Shah, Sultan, genic, and washable, and can gen- & Thakar, 2006). Modern pessaries erally be sterilized using an auto- are made from silicone, acrylic, clave, boiling water, or a cold ster- Shanna Atnip, MSN, WHNP-BC, is a Nurse latex, or rubber.
    [Show full text]
  • Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices
    September 12, 2006 NOTICE Our file number: 06-120629-368 Re: Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices Health Canada is pleased to announce the release of the revised Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices. This guidance document supersedes the January 14, 2000 version of the same document. The Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices is intended to assist manufacturers in confirming the classification of medical device products after application of the Classification Rules for Medical Devices set out in Schedule 1 of the Medical Devices Regulations. This guidance document has been revised to reflect changes to the risk- based classification of particular medical device groups. Specifically, the following major changes have been made to the document: • the reclassification of specific medical device groups; • the removal of redundant information; • the addition of medical device groups; and • the omission of product groups that do not fit the meaning of a medical device as defined in the Food and Drugs Act. To search for a medical device group within the Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices PDF file, go to Edit/Find and enter a keyword, preferred name code or description in the “Find” field. For instance, to verify the risk-based classification of dental burs, enter “bur” or “drill” in the “Find” field. Please note that this guidance document is provided only as a guide and that in the event of any discrepancy between this document and the Classification Rules for Medical Devices described in the Medical Devices Regulations, the latter shall prevail.
    [Show full text]
  • Treatment of Recurrent Vulvo-Vaginal Candidiasis with Sustained-Release Butoconazole Pessary
    C ase R eport Singapore Med J 2012; 53(12) : e269 Treatment of recurrent vulvo-vaginal candidiasis with sustained-release butoconazole pessary Ling Zhi Heng1, MBBS, Yujia Chen1, MBBS, Thiam Chye Tan1,2, MBBS, MMed ABSTRACT Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC. Keywords: butoconazole, candidiasis, recurrent vulvo-vaginal Singapore Med J 2012; 53(12): e269–e271 INTRODUCTION Table I. Risk factors for recurrent vulvo-vaginal candidiasis. Candidiasis is a common cause of infective vaginal discharge Risk factors Examples experienced by women. 75% of women experience at least Microbial • Candida albicans species one episode of vaginitis during their lifetime. Recurrent vulvo- • Non-albicans Candida species vaginal candidiasis (RVVC) is defined as four or more episodes Host • Uncontrolled diabetes mellitus • Oestrogen excess – oral contraceptive pills, hormone of symptomatic vulvo-vaginal cadidiasis (VVC) in one year. Up replacement therapy, local oestrogen administration, to 5% of women of childbearing age have experienced RVVC.(1) pregnancy Common symptoms include vaginal discharge, vulvar pruritus, • Antibiotic-induced dyspareunia and dysuria.
    [Show full text]
  • Drug-N-Therapeutics-Committee.Pdf
    Irrational use of medicines is a widespread problem at all levels of health care, but especially GUIDE DRUG AND THERAPEUTICS COMMITTEES: A PRATICAL in hospitals. This is particularly worrying as resources are generally scarce and prescribers in communities often copy hospital prescribing practices. Use of medicines can be greatly improved and wastage reduced if some simple principles of drug management are followed. But it is difficult to implement these principles because staff from many different disciplines are involved, often with no forum for bringing them together to develop and implement appropriate medicines policies. A drug and therapeutics committee (DTC) provides such a forum, allowing all the relevant people to work together to improve health care delivery, whether in hospitals or other health facilities. In many developed countries a well functioning DTC has been shown to be very effective in addressing drug use problems. However, in many developing countries DTCs do not exist and in others they do not function optimally, often due to lack of local expertise or a lack of incentives. Drug and Therapeutics Committees: A Practical Guide provides guidance to doctors, pharmacists, hospital managers and other professionals who may be serving on DTCs and/or who are concerned with how to improve the quality and cost efficiency of therapeutic care. It is relevant for all kinds of DTCs - whether in public or private hospitals and whether at district or tertiary referral level. This comprehensive manual covers a committee’s functions and structure, the medicines formulary process, and how to assess new medicines. The chapters on tools to investigate drug use and strategies to promote rational use are followed by a discussion of antimicrobial resistance and infection control.
    [Show full text]